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Abstract
Objective To assess the association between pandemic influenza A
(H1N1) 2009 vaccine and Guillain-Barré syndrome.
Design Case-control study.
Setting Five European countries.
Participants 104 patients with Guillain-Barré syndrome and its variant
Miller-Fisher syndrome matched to one or more controls. Case status
was classified according to the Brighton Collaboration definition. Controls
were matched to cases on age, sex, index date, and country.
Main outcome measures Relative risk estimate for Guillain-Barré
syndrome after pandemic influenza vaccine.
Results Case recruitment and vaccine coverage varied considerably
between countries; the most common vaccines used were adjuvanted
(Pandemrix and Focetria). The unadjusted pooled risk estimate for all
countries was 2.8 (95% confidence interval 1.3 to 6.0). After adjustment
for influenza-like illness/upper respiratory tract infection and seasonal
influenza vaccination, receipt of pandemic influenza vaccine was not
associated with an increased risk of Guillain-Barré syndrome (adjusted
odds ratio 1.0, 0.3 to 2.7). The 95% confidence interval shows that the
absolute effect of vaccination could range from one avoided case of
Guillain-Barré syndrome up to three excess cases within six weeks after
vaccination in one million people.
Conclusions The risk of occurrence of Guillain-Barré syndrome is not
increased after pandemic influenza vaccine, although the upper limit
does not exclude a potential increase in risk up to 2.7-fold or three excess
cases per onemillion vaccinated people.When assessing the association
between pandemic influenza vaccines and Guillain-Barré syndrome it
is important to account for the effects of influenza-like illness/upper
respiratory tract infection, seasonal influenza vaccination, and calendar
time.
Introduction
During the 2009 influenzaA (H1N1) pandemic, newmonovalent
adjuvanted and non-adjuvanted pandemic influenza A (H1N1)
vaccines were introduced in Europe. Documented
immunogenicity and safety was in line with the CHMP Note
for Guidance, but safety data were limited.1-8 Vaccination
campaigns started in autumn 2009 at the peak of the pandemic
in Europe.
A concern with the pandemic influenza A (H1N1) 2009 vaccine
was the possible occurrence of neuroimmunological adverse
events, including Guillain-Barré syndrome. A more than
sevenfold increased risk of Guillain-Barré syndrome was
observed with the swine origin influenza A (H1N1) subtype
A/NJ/76 vaccine applied in the United States in 1976,9 when
the vaccination campaign had to be discontinued abruptly.
Subsequent prospective surveillance studies10 11 and retrospective
epidemiological studies12 13 on seasonal influenza vaccines used
in 1978, 1979, 1980, 1992, 1993, and beyond showed no or
modest increases (up to twofold) in risk of Guillain-Barré
syndrome. Even though the studies repeatedly showed risk
estimates well below the sevenfold increase of 1976, they do
not provide reassurance that there is no increase in risk after
seasonal influenza vaccination. Small increases might surface
only during mass vaccination campaigns.
Guillain-Barré syndrome is an acute polyneuropathy, which, in
Europe, mostly presents as acute inflammatory demyelinating
polyradiculoneuropathy leading to progressive symmetrical
paresis.14-16 Guillain-Barré syndrome is fatal in 3-10% of cases
and leads to disability for more than six months in 20%.17 The
risk increases with age; reported incidence rates range between
0.4 and 4 per 100 000 person years.18
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The pathogenesis of the syndrome is not fully understood, but
it is usually preceded by specific gastrointestinal and respiratory
infections.19-21 Some infections might induce the production of
cross reactive antibodies to neural gangliosides,22 which cause
inflammatory neural damage. In 2008, Nachamkin et al reported
that 1976 influenza A (H1N1) vaccine was capable of inducing
cross reactive anti-GM1 in mice, supporting a causal relation
between the vaccination and Guillain-Barré syndrome.23
To date the role of influenza vaccinations as a trigger in
Guillain-Barré syndrome remains controversial. Two recent
studies from the United Kingdom found no supporting evidence
for a causal relation but rather identified influenza-like illness
as a strong risk factor.21 24 The results suggested a protective
effect of seasonal vaccination, possibly through the prevention
of influenza-like illness.21
Prospective monitoring of vaccine safety is essential in
maintaining public trust in vaccination campaigns.25 This and
the issues around Guillain-Barré syndrome in 1976 led the
European Centre for Disease Prevention and Control to
commission a prospective evaluation of any association between
pandemic influenza vaccines and Guillain-Barré syndrome.
Methods
Setting
The VAESCO (Vaccine Adverse Events Surveillance and
Communication) consortium conducted a distributed
case-control study. VAESCO is a growing network of
organisations (public health institutes, regulatory agencies, and
academic research centres) in Europe dedicated to improving
monitoring of safety of vaccines after licensing and was initiated
by the European Centre for Disease Prevention and Control.
Centres in Denmark, France, the Netherlands, Sweden, and the
UK participated in this study. The respective databases captured
a total source population of 50 million. All centres worked
according to a common protocol with a standardised case
definition and data collection form. Data were entered locally
through a common electronic data entry system. At each centre,
transformations were done by a standardised JAVA based
program (Jerboa version 2.6.0, Erasmus University Medical
Center, Rotterdam, Netherlands), which was verified by an
independent statistician (SR).26 Only completely anonymous
and de-identified datasets with no individual dates of disease
or exposure were shared for data pooling and centralised
analysis. Consent forms, original data, and Jerboa input files
were kept locally. Because of differences in healthcare structure
and availability of registries, the type of source population from
which cases and controls were recruited and the type of data
sources differed by country (see table 1). The coordinating centre
closely verified and queried data quality. The coordinating centre
and the national lead investigators ensured that, as far as
possible, information was collected in the same way from cases
and controls. The study period ran between 1 November 2009
and 30 March 2010.
Cases and controls
For this study we included cases of Guillain-Barré syndrome
and its variant Miller-Fisher syndrome. Each case was validated
according to the Brighton Collaboration definition of
Guillain-Barré syndrome, based on information obtained from
the reporting neurologist (France, Sweden, and Netherlands) or
from data in charts (UK, Denmark).14 All cases fulfilling the
case definition for Guillain-Barré syndrome or Miller Fisher
syndrome level 1-3 were included as well as any other cases
with a diagnosis confirmed by a neurologist. A sensitivity
analysis was conducted in which we restricted the cases to those
meeting Brighton Collaboration definition levels 1-3 only.
The index date was the earliest date of first symptoms or
diagnosis of Guillain-Barré syndrome. Table 1 summarises
country specific approaches to identification of cases and
controls. Each case was matched to up to 25 controls on age
(plus or minus one year), sex, index date, and country.
Exposure classification
The primary exposure of interest was pandemic influenza
vaccination during a risk window of one day to six weeks before
the index date. Exposure was further classified according to the
brand of vaccine (Pandemrix, Focetria, Celvapan, Panenza, or
other) and dose (first or second). Vaccination occurring more
than six weeks before was classified as past exposure.9Unknown
vaccination dates were categorised separately. Data on pandemic
influenza vaccination were obtained from vaccine registries in
Denmark and France, from general practitioner records in the
UK and the Netherlands, and through structured interviews in
Sweden.
Control for confounding
Information on the following covariates was collected with a
standardised data collection form in each country: history of
Guillain-Barré syndrome, Epstein-Barr virus infection,
malignancy, immunosuppression, autoimmune disorder,
gastrointestinal infections, influenza-like illness or upper
respiratory tract infection, and other vaccinations (especially
seasonal influenza vaccination). For influenza-like illness or
upper respiratory tract infection, gastrointestinal infection, and
seasonal influenza vaccination, the risk window comprised the
six weeks before the index date, not including the index date
itself. Seasonal influenza vaccination (2009-10 season) more
than six weeks before the index date was classified as past
exposure. Information on covariates was retrieved from general
practice records in the UK and the Netherlands, from hospital
medical records in France, and by structured interview in
Sweden. In Denmark, information on covariates was obtained
through chart review of the cases only and therefore could not
be used for statistical adjustments.
Statistical analysis
Matched odds ratios and 95% confidence intervals were
calculated with multivariate conditional logistic regression. “No
vaccination” in the six weeks before the index date served as
the reference category. Variables considered for inclusion in
the final model were those that were associated with
Guillain-Barré syndrome in the univariate matched analysis at
P<0.1; they were retained in the final model if they changed the
point estimate of the association between the pandemic influenza
vaccine and Guillain-Barré syndrome by more than 10%.27 We
conducted age stratified analyses to estimate the association
with pandemic influenza vaccination in different age groups.
We explored interactions between pandemic influenza
vaccination and the main confounders by applying population
restrictions but had insufficient power for statistical testing
because of the low prevalence of exposure.
We carried out sensitivity analyses regarding disease and
misclassification of exposure to pandemic influenza vaccination
to assess robustness of the results. Exposure misclassification
was addressed with three approaches: with all people with
unknown dates of vaccination considered as exposed; with all
people with unknown dates of vaccination considered as
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unexposed; and with all exposures more than six weeks before
classified as non-exposure.
Risk estimates across countries were pooled with a
meta-analytical approach to account for the differences in
exposure prevalence. We used a random effects model to
account for heterogeneity between countries.28 For all analyses
significance was accepted at a two sided P<0.05. Analyses were
done in SPSS 15.0 for windows (release 15.0, 2006, SPSS,
Chicago, IL).
Results
Study population
From a source population of about 50 million in the five
countries, 154 cases of Guillain-Barré syndromewere identified.
Of these, 104 could be matched to one or more controls. Many
unmatched cases were from France, where timely recruitment
of controls was problematic. Comparison of the number of
patients with Guillain-Barré syndrome in hospital claims
registries in the Netherlands suggested around 50%
under-reporting of cases omitted for the study. The uptake of
pandemic influenza A (H1N1) 2009 vaccine in excluded cases
was similar to that in the included cases.
Most cases were men, aged 46-61 (table 2) and had Brighton
Collaboration case classification level 1 to 3. In countries with
retrospective chart or medical record review (Denmark and UK)
the available information did not always allow for Brighton
Collaboration classification, mostly because information
regarding symptoms and diagnostic processes was not recorded
to the required level of detail and could not be retrieved
retrospectively. Acute inflammatory demyelinating
polyradiculoneuropathy was the most common type of
Guillain-Barré syndrome. Six patients (5.8%) had a disability
score of 5 (ventilator treatment required) or 6 (fatal).
Chronic comorbidity was rare; malignancy and
immunocompromise were the most common comorbid
conditions, but these were not associated with Guillain-Barré
syndrome. Acute infections in the six weeks leading up to the
index date were more common and occurred mostly in cases
(table 3). Most infections were influenza-like illness/upper
respiratory tract infections. They were strongly associated with
Guillain-Barré syndrome, with odds ratios ranging from 4.9
(95% confidence interval 1.6 to 15.5) in the UK to 19.3 (5.9 to
63.4) in the Netherlands.
Vaccinations
Pandemrix was the most widely used pandemic influenza A
(H1N1) 2009 vaccine in the study population as this was the
main brand used in Denmark, Sweden, and the UK. In the
Netherlands Focetria was the predominant vaccine, but
Pandemrix was used in children aged below 6. Other brands
were used only rarely. Vaccine uptake was highest in the
Netherlands and Sweden and was much lower (<10% of study
population) in the UK, Denmark, and France (table 4). In each
country, exposure to the vaccine in unmatched cases was similar
to that in matched cases. Exposure prevalence among unreported
cases in the Netherlands was similar to that of cases in the study.
Seasonal influenza vaccination coverage in the Netherlands was
similar to pandemic influenza vaccination coverage but
consistently occurred earlier and therefore was more often
classed as past exposure (table 4). In the UK seasonal influenza
vaccination was more common than pandemic influenza
vaccination, and there was evidence of an increased risk of
Guillain-Barré syndrome with recent exposure to seasonal
influenza vaccination (odds ratio 6.3 (1.8 to 22.0) with no
adjustment for influenza-like illness/upper respiratory tract
infections; 5.1 (1.4 to 18.6) with adjustment). In Sweden the
recorded uptake of seasonal influenza vaccination was low and
potentially incomplete. For Denmark and France, no information
on seasonal influenza vaccination was available for controls.
No cases were exposed to other types of vaccination in the six
weeks before the index date.
Guillain-Barré syndrome and pandemic
influenza vaccination
Unadjusted matched analyses resulted in risk estimates for
Guillain-Barré syndrome with pandemic influenza vaccination
that ranged from 1.3 to 2.5 in the UK, Sweden, and Netherlands
(table 5). The risk estimate in Denmark, based on two exposed
cases, was 9.5 (1.7 to 53). Both cases had extensive comorbidity
but no influenza-like illness/upper respiratory tract infections
or gastrointestinal infections recorded in the charts. We could
not calculate an estimate for France because there was only one
exposed case and no exposed controls. There was no difference
in risk between Pandemrix and Focetria, although the products
could not be compared within countries. Two doses of pandemic
influenza vaccination as provided in the Netherlands seemed to
be associated with a higher risk of Guillain-Barré syndrome
(table 5).
The increase in risk of Guillain-Barré syndrome associated with
pandemic influenza vaccination in the unadjusted analyses
disappeared when we adjusted the results for influenza-like
illness/upper respiratory tract infections and seasonal influenza
vaccination. Adjusted risk estimates for the Netherlands and
the UK, where information on both variables was available,
were 0.6 (0.1 to 4.4) and 0.7 (0.1 to 4.1), respectively (table 5).
The test for homogeneity in effect estimates across the four
countries was not significant (P=0.40), but, because of lack of
power of the test and the differences observed, we used a random
effects model for the weighted pooling. The crude matched risk
for Guillain-Barré syndrome was 2.8 (1.3 to 6.0). The random
effects risk estimate adjusted for seasonal influenza vaccination
and influenza-like illness/upper respiratory tract infections for
the Netherlands, UK, and Sweden was 1.0 (0.3 to 2.7, P=0.81
for homogeneity). As Swedish data did not capture seasonal
influenza vaccination well and might be subject to selection and
recall bias, we conducted a sensitivity analysis without Sweden.
The pooled adjusted odds ratio was 0.7 (0.2 to 2.5) (table 6).
Denmark could not be included in the adjusted analyses because
information on influenza-like illness/upper respiratory tract
infections and seasonal influenza vaccination was unavailable
for the controls.
Restricted and stratified analyses
In people without influenza-like illness/upper respiratory tract
infections the risk of Guillain-Barré syndrome after pandemic
influenza vaccination was higher but not significant and was
unstable (table 5). The effect shrank on adjustment for seasonal
influenza vaccination. Similarly, influenza-like illness/upper
respiratory tract infections had a strong confounding effect in
people without seasonal influenza vaccination. As recorded
seasonal influenza vaccination in Sweden was possibly
incomplete we could explore confounding only by influenza-like
illness/upper respiratory tract infections, which again was
substantial (matched odds ratio for Swedish population without
influenza-like illness/upper respiratory tract infections was 1.3,
0.2 to 8.1).
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Cases in children were rare (9%, table 2). Most cases were in
people aged 19-59 (n=57, 55%), in whom uptake of pandemic
influenza A (H1N1) 2009 vaccine was low (exposure in controls
4%). Uptake of the vaccine was higher in those aged over 60
(10% in controls). Risk estimates for those aged 19-59 and 60
and over did not differ significantly (4.9 (1.3 to 17.9) v 2.7 (0.8
to 9.1)). Below the age of 19 the risk estimate seemed high but
this was unstable because of too few exposed people (one case
and two controls).
Sensitivity analyses
We carried out various sensitivity analyses to assess the impact
of misclassification of the outcome and exposure as well as
residual confounding. Restricting the cases to Brighton
Collaboration case classification levels 1 to 3 did not materially
alter the risk estimates (pooled random effects adjusted odds
ratio 0.9, 0.2 to 4.6). Extending the risk window for pandemic
influenza A (H1N1) 2009 vaccine to any time before the index
date reduced this to 0.7 (0.3 to 1.9). Considering people with
missing dates of pandemic influenza vaccination as exposed in
the risk window reduced the estimate to 0.8 (0.3 to 2.3) as data
weremissingmostly in controls. Considering them as unexposed
had no effect on the estimate. Excluding Sweden (the only
country with interview based assessment of exposure and
covariates) from the pooled analyses changed the adjusted
pooled random effects estimate from 1.0 to 0.7 (0.2 to 2.5) (table
6).
Discussion
Principal findings
In a source population of around 50 million people in Europe
we could not find any association between adjuvanted pandemic
influenza A (H1N1) 2009 vaccine and Guillain-Barré syndrome
(adjusted odds ratio 1.0, 95% confidence interval 0.3 to 2.7).
The increased risk in the unadjusted analyses disappeared when
we adjusted for the apparent strong confounding of
influenza-like illness/upper respiratory tract infections and
seasonal influenza vaccination. Based on the 95% confidence
interval for the adjusted odds ratio it is unlikely that the relative
risk is above 2.7. Thus it is unlikely that there would be more
than one excess case of Guillain-Barré syndrome per 340 000
vaccinated people (or three per million) given a risk window of
six weeks and a background incidence rate of 1.5 per 100 000
person years.
The effects of adjustment for seasonal influenza vaccination
were strong but differed between countries, which could be
explained by differences in vaccination strategies. In the
Netherlands the population targeted for pandemic influenza A
(H1N1) 2009 vaccine overlapped largely with the population
targeted for seasonal influenza vaccination, whereas in the UK
it only partially overlapped as not all older people were targeted
for pandemic influenza A (H1N1) 2009 vaccination. In Sweden,
pandemic influenza A (H1N1) 2009 vaccine wasmade available
to the entire population, but there was under-reporting of
seasonal influenza vaccination so that we could not appropriately
adjust for it.
Relation to other studies
The VAESCO consortium is one of the first groups to provide
data on the association between pandemic influenza A (H1N1)
2009 vaccines and Guillain-Barré syndrome with substantial
power and mostly adjuvanted vaccines. Our results are
comparable with those of a study investigating the risk of
Guillain-Barré syndrome with non-adjuvanted pandemic
influenza A (H1N1) 2009 vaccine in the US, which showed an
age adjusted rate ratio of 1.77 (1.12 to 2.56).29 In the USVaccine
Safety Datalink no increased risk of adverse events was
identified after administration of 1 195 552 doses of
non-adjuvanted vaccine to people aged under 18 and 4 773 956
doses to adults.30 Those studies made no statistical adjustment
for influenza-like illness/upper respiratory tract infections and
seasonal influenza vaccination.
Influenza-like illness/upper respiratory tract infections are a
recognised risk factor for Guillain-Barré syndrome,16 as
confirmed in our study. The association with influenza-like
illness shown previously in the UK General Practice Research
Database was stronger (18.0 (7.5 to 46.4) for influenza-like
illness and 5.2 (3.5 to 7.6) for acute respiratory tract infections)
than in our study (4.9 (1.6 to 15.5) for influenza-like
illness/upper respiratory tract infections and predominantly
comprising upper respiratory tract infections).21
Several vaccines have been associated with Guillain-Barré
syndrome,31-33 but controversy remains for the influenza
vaccines.9 12 13 20 34 35A recent study found no association between
seasonal influenza vaccination and Guillain-Barré syndrome,24
whereas our study showed an increased risk. Different
circumstances and differences in study design could explain
this discrepancy. The previous study was a self controlled case
series, had differential case verification, and used data up to
2005. In 2009, during the study period of the present study,
seasonal influenza vaccinations were supplied while the
pandemic was coming to its peak. As in most countries
pandemic influenza vaccines became available only after the
seasonal vaccination campaign, people with influenza symptoms
might have had a higher uptake of seasonal influenza
vaccination. If there was under-reporting of influenza-like illness
in the General Practice Research Database, because patients
were discouraged to visit the general practitioner for such
symptoms in the UK in 2009, seasonal influenza vaccination
could therefore be a proxy for influenza-like illness. This could
explain why the effect of seasonal influenza vaccination was
higher than expected in the General Practice Research Database.
Strengths and weaknesses
By combining data from several European countries we showed
consistency of the risk estimate across countries and we could
increase the sample size by pooling data that were collected,
transferred, and analysed in a standardised way, reducing
heterogeneity between study sites. By pooling through
meta-analysis we accounted for population size and differences
in exposure prevalence.28 Moreover, the differences in data
collection between countries allowed us to establish the impact
of potential biases.
Because this study was conducted in a pandemic situation it
also has limitations, especially given the increased awareness
of a potential increase in the risk of Guillain-Barré syndrome
associated with pandemic influenza vaccination. As a
consequence, people at increased baseline risk (such as those
with a history of the syndrome) might be less likely to have
received the vaccine and there could have been over-reporting
or selective inclusion of exposed people with Guillain-Barré
syndrome in the participating countries.
In the Netherlands there was under-reporting of cases, but
verification against objective claims data suggested this was
non-differential with regards to exposure. In Sweden and France,
there were substantial delays in inclusion of cases, and
selectiveness could not be fully assessed as data on non-included
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patients were not available. In the UK and Denmark, patient
consent was not required, which should reduce the likelihood
of differential under-reporting. This assumption, however, could
not be verified with the available data. A priori we had assumed
that any selection would work in the direction of including more
exposed cases as many physicians were aware of the potential
risk. The latter would have resulted in an overestimated risk,
which does not seem to have affected our study as we did not
find an increased risk.
Misclassification of the timing of pandemic influenza A (H1N1)
2009 vaccine, as reflected by the amount of missing information
on vaccination, occurred mostly in controls, suggesting more
accurate collection of data for cases, especially in Sweden.
Sweden was the only country in which exposure was collected
by interview rather than a registry, which could have introduced
recall bias. Sensitivity analyses addressing this particular issue
showed that complete information on all dates would have
resulted in even lower risk estimates.
We addressed important confounders by matching (age, sex,
calendar time, and country) and by adjusting in a multivariate
analysis. Adjustment for influenza-like illness/upper respiratory
tract infection and seasonal influenza vaccination had strong
effects on the risk estimates and caused the pooled estimate to
reduce from 2.8 to 1.0. Both factors were positively associated
with pandemic influenza vaccination and also with
Guillain-Barré syndrome. In particular seasonal influenza
vaccination and pandemic influenza vaccination were strongly
associated with each other and adjustment for seasonal
vaccination had the most pronounced effect on the effect
estimate, as shown in table 5, both in the UK and the
Netherlands. As argued above, seasonal influenza vaccination
could be a proxy for being at high risk for complications
associated with influenza or for having influenza symptoms as
the seasonal vaccination was supplied at the beginning of the
pandemic when there was fear of the consequences and the
pandemic influenza vaccination was not yet supplied.
Residual confounding will exist for the countries where
information on influenza-like illness/upper respiratory tract
infection or seasonal influenza vaccination was (partly)
unavailable, such as in Denmark, Sweden (seasonal vaccination),
and France. Differential recording of risk factors for
Guillain-Barré syndrome cannot be ruled out and hence more
information regarding these risk factors might have been
available for cases than for controls, especially if cases were
recruited through neurologists. This would have resulted in an
underestimated risk. Recall bias in the Swedish data cannot be
ruled out as information was gathered from cases and controls
by interview. In the UK information on covariates was obtained
similarly for cases and controls, showing slightly less impact
of influenza-like illness/upper respiratory tract infection, and
the adjusted risk estimate showed no association. The relatively
low impact of influenza-like illness/upper respiratory tract
infection on Guillain-Barré syndrome in the UK could also be
the consequence of non-differential false negative
misclassification of infections: patients were advised not to visit
their general practitioner for influenza-like illness.
Meaning of the study
In our opinion the study contributes at least four pieces of
important information. The quantification of the association
between Guillain-Barré syndrome and adjuvanted pandemic
influenza vaccines allows for subsequent assessment of benefit
to risk. Our point estimate shows no association between
pandemic influenza vaccination and Guillain-Barré syndrome,
although the upper confidence limit is 2.7. In terms of absolute
risk, on the basis of the upper confidence limit the absolute risk
would be less than three excess cases after one million
vaccinations. This is well below the observed increase in risk
with the 1976 swine origin influenza A (H1N1) subtype A/NJ/76
vaccine applied in the US, which was reported to be sevenfold.
The consistent pattern across countries provides reassurance
about the findings. The study also highlights the added value
of an international data linkage study with a single protocol, a
common data model, and a uniform analysis plan for the
assessment of vaccine safety.
Unanswered questions and future research
Residual confounding by unmeasured patients’ characteristics
that are not time dependent (such as the underlying reason for
being eligible for vaccination) can be studied with a self
controlled case series design. VAESCO is finalising such a
study of the association between pandemic influenza A (H1N1)
2009 vaccination and Guillain-Barré syndrome in seven
countries. The series will include the cases from the study
presented here supplemented with unmatched cases and cases
from additional countries over a longer period. It will also
eliminate any differential recording of confounders between
cases and controls.
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What is already known on this topic
The swine origin influenza A (H1N1) subtype A/NJ/76 vaccine used in the US in 1976 was associated with a more than
sevenfold increased risk of Guillain-Barré syndrome
Subsequent studies repeatedly showed only a slight to no increase in risk after seasonal influenza vaccination during
later seasons
In 2009 mass vaccination with new adjuvanted pandemic influenza A (H1N1) 2009 vaccines started in Europe, but it
was unknown if these vaccines were associated with an increased risk of Guillain-Barré syndrome
What this study adds
Adjuvanted pandemic influenza A (H1N1) 2009 vaccines did not increase the risk of Guillain-Barré syndrome substantially,
if at all
Influenza-like illness and upper respiratory tract infection are important covariates in the association between influenza
vaccination and Guillain-Barré syndrome
Multinational data linkage based on a single protocol, common data model, and uniform analysis plan for collaborative
and prospective investigation of important potential vaccine safety issues is feasible
and approved the drafts of the manuscript. Piotr Kramarz and KJ
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Tables
Table 1| Sources for cases, controls, exposure, and covariates by country in study of association between pandemic influenza A (H1N1)
2009 vaccine and Guillain-Barré syndrome
Covariates
Exposure to H1N1
vaccinationMatchingControlsCasesCountry
From GP record
for cases and
controls
From automated GP
records, no recall bias.
Non-differential
misclassification possible
as some people might
have been vaccinated
outside of GP office
Sex, age,
practice,
index date
Controls selected randomly from
GPRD, matched on age, sex, practice,
and index date to case. Consent not
required. No selection bias expected
Each case identified from GPRD by using
appropriate READ codes (F370.00, F370000,
F370100, F370200, F370z00). Case verification
done with free text, scanned hospital letters as
well as GPs’ notes regarding diagnostic
procedures. No major selection bias expected
UK
From medical
charts for cases
only)
From vaccination
registry, no recall bias
Sex, age,
index date
Controls selected randomly from
Danish civil registration system. Up to
20 controls matched to case on age,
sex, and index date. Consent not
required. No selection bias expected
Cases identified from National Patient Register
with primary discharge diagnoses only (ICD-10
code: G61.0). Case verification done after
obtaining charts from cases. Potential small
selection bias because of incomplete availability
of charts
Denmark
From GP records
for cases and
controls
From GP record. No
recall bias
Non-differential
misclassification possible
as some people might
have been vaccinated
outside of GP office
Sex, age,
practice,
index date
Controls were identified from GP of
case patients. 10 patients randomly
selected from list of registered patients
and matched to case on age, sex,
index date, and practice. Consent not
required. No selection bias expected
Cases identified prospectively through
neurologists. Completeness verified
retrospectively by checking against claims codes
in each of reporting hospitals. Consent not
required. Missing patients included retrospectively
as far as possible. Verification of reporting against
vaccination status showed incomplete reporting
but non-differential regarding vaccinations
Netherlands
Medical records
for both cases and
controls
From registry. No recall
bias
Sex, age,
hospital,
index date
Controls obtained from trauma unit in
same hospital. Controls needed to
provide informed consent. Response
incomplete. Not possible to assess
whether non-response differed by
vaccination status and hence cannot
exclude selection bias
Cases identified prospectively through
neurologists in seven reference hospitals in
France. Patients needed to provide informed
consent. Completeness verified against pharmacy
data (immunoglobulin prescriptions) and showed
incomplete reporting (<50%). Vaccination status
of non-reported cases could not be verified as
linkage to vaccination registry required consent
France
By interview for
cases and
controls. Charts
reviewed for case
verification
By interview, cannot
exclude recall bias
Sex, age,
index date
Controls selected randomly from
Swedish national population registry.
Controls needed to provide informed
consent. Response incomplete. Not
possible to assess whether
non-response differed by vaccination
Cases identified through seven neurology
assessment laboratories where cases are
laboratory confirmed for population of 9.4 million.
Informed consent needed from all cases.
Completeness of cases was checked in National
Patient Registry for part of country. Recruitment
Sweden
status and hence cannot exclude
selection bias
incomplete because of delays in consent and
non-consent. Not possible to assess whether this
non-response differed by vaccination status and
hence cannot exclude selection bias
GPRD=General Practice Research Database.
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Table 2| Recruitment of cases with Guillain-Barré syndrome and coverage with pandemic influenza A (H1N1) vaccination by country
PooledFranceDenmark†UK*SwedenNetherlands
—Pandemrix (Celvapan,
Focetria, Panenza)
PandemrixPandemrix (Celvapan,
Focetria)
PandemrixFocetria (Pandemrix in
children)
Brand used
7-8686233Vaccination coverage (%)‡
49.410-205.53.59.416Approximate source population
(million)
29962-25342259100Expected No of cases in study period§
1543724342633No of cases recruited
104724301825No of cases with ≥1 control
11982159030060227Total No of controls
13022861433078252Total study population
Characteristics of cases (No (%) unless stated otherwise)
50 (22)61 (16)48 (19)48 (23)55 (20)46 (23)Mean (SD) age (years)
9 (9)01 (4)4 (13)04 (16)Age ≤18
57 (55)3 (43)16 (67)16 (53)9 (50)13 (52)Age 19-59
38 (37)4 (57)7 (29)10 (33)9 (50)8 (32)Age ≥60
62 (60)4 (58)14 (57)17 (57)13 (73)14 (56)Male
Brighton Collaboration case classification:
32 (31)4 (57)7 (29)011 (61)10 (40)Level 1
23 (22)2 (29)8 (33)03 (17)10 (40)Level 2
10 (10)03 (13)04 (22)3 (12)Level 3
39 (38)1 (14)6 (25)30 (100)02 (8)Neurologist confirmed but not level
1-3
*UK stopped recruitment of cases and controls for case-control study on 2 Feb 2010.
†Register from which cases identified in Denmark ran until end of December 2009.
‡Based on VENICE data.
§Based on 1.5 per 100 000 person years (IR) and 5 month study period: IR*source population*5/12.
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Table 3| Distribution of chronic comorbidity and infections in cases and controls by country in study of association between pandemic
influenza A (H1N1) 2009 vaccine and Guillain-Barré syndrome. Figures are numbers (percentages)
DenmarkFranceUKSwedenNetherlands
Case
(n=24)
Control
(n=590)*
Case
(n=7)
Control
(n=21)
Case
(n=30)
Control
(n=300)
Case
(n=18)Control (n=60)
Case
(n=25)
Control
(n=227)
Chronic comorbidity
0NA008 (27)47 (16)04 (7)2 (8)6 (3)
Autoimmune
disease
1 (4)NA001 (3)0001 (4)0
History of
Guillain-Barré
0NA001 (3)1 (0.3)002 (8)12 (5)Epstein Barr virus
1 (4)NA1 (14)3 (14)2 (7)16 (5)2 (11)4 (7)1 (4)12 (5)Malignancy
0NA02 (10)4 (13)26 (9)1 (6)01 (4)5 (2)
Immune
compromised
Infections in 6 weeks before
2 (8)NA2 (29)0004 (22)1 (2)2 (8)1 (0.4)
Gastrointestinal
infection
4 (17)NA0001 (0.3)2 (11)08 (32)3 (1)Influenza-like illness
0NA2 (29)05 (17)11 (4)4 (22)3 (5)8 (32)10 (4)
Upper respiratory
tract infection
4 (17)NA2 (29)05 (17)12 (4)6 (33)3 (5)12 (48)13 (6)
Influenza-like illness
or upper respiratory
tract infection (%)
*NA=not available. No information collected on covariates.
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Table 4| Influenza vaccinations in cases and controls according to timing of vaccination (≤6 weeks or >6 weeks) before onset of symptoms
and brand. Figures are numbers (percentages)
DenmarkFranceUKSwedenNetherlands
CaseControlCaseControlCaseControlCaseControlCaseControl
Pandemic influenza A (H1N1) 2009 vaccine
20 (83)568 (96)5 (71)20 (95)28 (93)279 (93)7 (39)23 (38)13 (52)149 (66)None
2 (8)6 (1)1 (14)02 (7)16 (5)6 (33)11 (18)6 (24)33 (15)≤6 weeks*
Dose:
2 (8)6 (1)002 (7)16 (5)6 (33)11 (18)2 (8)26 (12)1 dose
001 (14)002 (2)004 (16)7 (3)2 doses
Brand:
2 (8)6 (1)002 (7)13 (4)6 (33)11 (18)00Pandemrix
000000006 (24)33 (15)Focetria
001 (14)0000000Panenza
000003 (1)0000Unknown
2 (8)16 (3)0005 (2)4 (22)14 (23)6 (24)42 (19)>6 weeks†
001 (14)1 (5)001 (6)12 (20)03 (1)Unknown timing
Seasonal influenza vaccination
0NA0019 (63)222 (74)18 (100)53 (88)13 (52)145 (64)None
0NA007 (23)28 (9)02 (3)2 (8)24 (11)≤6 weeks*
0NA004 (13)50 (17)03 (5)10 (40)57 (25)>6 weeks†
0NA000002 (3)01 (0.4)Unknown timing
NA=not available.
*Vaccine given ≤6 weeks before index date (earliest date of first symptoms or diagnosis of Guillain-Barré syndrome).
‡Vaccine given >6 weeks before index date.
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Table 5| Crude and adjusted relative risk estimates (odds ratio and 95% confidence intervals) for Guillain-Barré syndrome after pandemic
influenza A (H1N1) 2009 vaccination according to timing of vaccination (≤6 weeks or >6 weeks) before onset of symptoms
Adjusted for seasonal influenza
vaccination and ILI/URTI
Adjusted for seasonal influenza
vaccination onlyILI/URTI adjusted onlyUnadjusted matched analysis*
Denmark:
———ReferenceNone
———9.5 (1.7 to 53)≤6 weeks
———3.4 (0.7 to 17)>6 weeks
Netherlands:
ReferenceReferenceReferenceReferenceNone
0.6 (0.1 to 4.4)1.7 (0.3 to 8.8)1.3 (0.3 to 6.1)2.5 (0.7 to 9.3)≤6 weeks
0.2 (0.01 to 4.3)0.5 (0.1 to 5.1)0.2 (0.0 to 4.2)0.7 (0.1 to 6.0)1 dose
6.9 (0.6 to 81.0)6.2 (1.1 to 35.4)5.3 (0.6 to 44.1)6.8 (1.3 to 36)2 doses
0.2 (0.02 to 1.6)0.7 (0.1 to 4.8)0.9 (0.2 to 4.2)1.7 (0.4 to 6.4)>6 weeks
NCNCNCNCMissing dates
Sweden†:
Reference†Reference†ReferenceReferenceNone
1.8 (0.3 to 12)2.4 (0.5 to 11.8)1.8 (0.3 to 10.7)2.3 (0.5 to 11.7)≤6 weeks
1.3 (0.2 to 8.5)1.2 (0.2 to 6.3)1.0 (0.2 to 6.3)0.9 (0.2 to 4.9)>6 weeks
0.6 (0.1 to 6.8)0.4 (0.0 to 4.0)0.5 (0.0 to 5.5)0.3 (0.03 to 3.5)Missing date
UK:
ReferenceReferenceReferenceReferenceNone
0.7 (0.1 to 4.1)0.7 (0.1 to 4.2)1.1 (0.2 to 5.7)1.3 (0.3 to 6.4)≤6 weeks
NCNCNCNC>6 weeks
ILI/URTI=influenza-like illness or upper respiratory tract infection; NC=not calculated because of low numbers.
*Matched on age (within 1 year), sex, and index date; additionally matched on GP practice in Netherlands and UK
†No cases exposed to seasonal influenza vaccination (possible under-reporting).
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Table 6| Crude and adjusted relative risk estimates (odds ratio and 95% confidence intervals) from pooled analyses for Guillain-Barré
syndrome after pandemic influenza A (H1N1) 2009 vaccination given ≤6 weeks before onset of symptoms
Adjusted for seasonal influenza
vaccination and ILI/URTI
Adjusted for seasonal influenza
vaccination onlyILI/URTI adjusted onlyUnadjustedmatched analysis*
No exposure as reference
———2.8 (1.3 to 6.0)Netherlands, UK, Sweden,
Denmark
1.0 (0.3 to 2.7)1.5 (0.6 to 3.9)1.4 (0.5 to 3.5)2.0 (0.9 to 4.8)Netherlands, UK, Sweden
0.7 (0.2 to 2.5)1.2 (0.4 to 3.8)1.2 (0.4 to 3.7)1.9 (0.7 to 5.3)Netherlands, UK
Restricted to people without ILI/URTI; no exposure as reference
—1.2 (0.4 to 4.0)—1.9 (0.7 to 5.6)Netherlands, UK, Sweden
—1.2 (0.3 to 5.8)—2.5 (0.6 to 10.7)Netherlands, UK
ILI/URTI=influenza-like illness or upper respiratory tract infection.
*Matched on age (within 1 year), sex, and index date; additionally matched on GP practice in Netherlands and UK.
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